Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey.
Anti-Bacterial Agents
/ therapeutic use
Carbapenems
/ therapeutic use
Cohort Studies
Communicable Diseases
/ drug therapy
Critical Care
/ standards
Cross-Sectional Studies
Drug Resistance, Multiple, Bacterial
Enterobacteriaceae
/ drug effects
Global Health
Humans
Infection Control
Intensive Care Units
/ standards
Microbial Sensitivity Tests
Physicians
/ classification
Antimicrobials
Colonization
Infection control
Intensive care
Multidrug-resistant bacteria
Prevention
Sepsis
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
31
01
2019
accepted:
05
03
2019
pubmed:
23
3
2019
medline:
15
11
2019
entrez:
23
3
2019
Statut:
ppublish
Résumé
To identify differences in perception on multi-drug-resistant (MDR) organisms and their management at intensive care units (ICU). A cross-sectional survey was conducted. A proposal addressing a pathogen priority list (PPL) for ICU, arising from the TOTEM study, was compared with a sample of global experts in infections in critically ill patients. The survey was responded by 129 experts. Globally, ESBL Enterobacteriaceae, followed by carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Klebsiella pneumoniae, were the main concerns. Some differences in opinion were identified between 63 (49%) ICU physicians (ICU/anesthesiology) and 43 (33%) infectious disease consultants (ID physicians/microbiologists). The pathogens most concerning in the ICU for intensivists were ESBL Enterobacteriaceae (38%) versus carbapenem-resistant A. baumannii (48.3%) for ID consultants, (p < 0.05). Increasing number of ID consultants over intensivists (26% vs 14%) reported difficulty in choosing initial therapy for carbapenem-resistant A. baumannii. For intensivists, the urgent measures to limit development of antibiotic resistance were headed by cohort measures (26.3%) versus increasing nurse/patient ratio (32.5%) for ID consultants, (p < 0.05). Regarding effectiveness to prevent MDR development and spread, education programs (42.4%) were the priority for intensivists versus external consultation (35.7%) for ID consultants. Finally, both groups agreed that carbapenem resistance was the most pressing concern (> 70%) regarding emerging resistance. Differences in priorities regarding organisms, infection control practices, and educational priorities were visualized between ID/clinical microbiologists and ICU/anesthesiologists. Multi-disciplinary collaboration is required to achieve best care for ICU patients with severe infections.
Identifiants
pubmed: 30900056
doi: 10.1007/s10096-019-03530-1
pii: 10.1007/s10096-019-03530-1
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1235-1240Subventions
Organisme : Wellcome Trust
ID : 205214/Z/16/Z
Pays : United Kingdom
Références
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv43-iv48
pubmed: 21521706
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Clin Infect Dis. 2015 Jul 15;61(2):155-6
pubmed: 25824816
J Infect Dev Ctries. 2015 Oct 29;9(10):1040-5
pubmed: 26517477
Emerg Microbes Infect. 2016 Mar 23;5:e27
pubmed: 27004762
Am J Infect Control. 2016 Nov 1;44(11):1296-1301
pubmed: 27339791
Elife. 2016 Sep 06;5:
pubmed: 27599374
PLoS One. 2016 Oct 24;11(10):e0165242
pubmed: 27776162
J Infect. 2017 Feb;74(2):131-141
pubmed: 27838521
Lancet Infect Dis. 2017 Feb;17(2):153-163
pubmed: 27866944
J Infect Dis. 2017 Feb 15;215(suppl_1):S9-S17
pubmed: 28375515
Intensive Care Med. 2017 Aug;43(8):1164-1166
pubmed: 28409204
Intensive Care Med. 2018 Jan;44(1):79-82
pubmed: 28409205
Infect Control Hosp Epidemiol. 2017 Jul;38(7):848-856
pubmed: 28566096
Semin Respir Crit Care Med. 2017 Jun;38(3):253-263
pubmed: 28578550
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2155-2163
pubmed: 28624864
Clin Infect Dis. 2017 Nov 13;65(11):1921-1923
pubmed: 29020322
Am J Infect Control. 2018 Sep;46(9):1060-1068
pubmed: 29661630
Clin Infect Dis. 2019 Jan 18;68(3):519-524
pubmed: 30020449
Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):319-323
pubmed: 30426331
JAMA. 1995 Aug 23-30;274(8):639-44
pubmed: 7637145